Literature DB >> 2210911

Activation of T-cells by bryostatins: induction of the IL-2 receptor gene transcription and down-modulation of surface receptors.

A H Esa1, W O Boto, W H Adler, W S May, A D Hess.   

Abstract

Bryostatins are macrocyclic lactones isolated from the marine bryozoan Bugula neritina. They are currently evaluated for putative antineoplastic activity. Bryostatins bind and activate protein kinase C (PK-C), the cellular receptor for the phorbol ester, and elicit PK-D-dependent cellular functions. Such functions include the expression of the interleukin-2 receptor (IL-2R). Northern blot hybridization with a human IL-2R and an IL-2 cDNA showed that bryostatin 1 (bryo 1), like the phorbol ester, PMA, activates the IL-2R gene. Activation with bryo 1 or PMA in the presence of a calcium ionophore, A23187, increased IL-2 message. These findings indicate that calcium mobilization is necessary for bryo 1 or PMA induced IL-2 gene expression. Unlike PMA, bryo 1 did not cause a vigorous proliferative response of T-lymphocytes unless A23187 was added to the cultures. A bryostatin congener, bryo 13, was inactive in the above assays. Short-term treatment of T-cells with bryo 1 and PMA resulted in an equivalent down-regulation of surface CD3 and CD4 receptors without affecting the CD8 receptor. Bryo 1 or PMA mediated expression of surface IL-2R and T-cell proliferation induced by bryo 1 or PMA were sensitive to inhibition by the PK-C antagonists staurosporine (Sts) and H-7. In contrast, CD4 and CD3 down-regulation were resistant to H-7, but could be blocked by Sts, although the Sts concentration required to block bryo 1 or PMA-induced down-modulation was 2.5-fold higher than required to inhibit IL-2R expression and T-cell proliferation. These results indicate that bryostatins activate T-cell through PK-C.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2210911     DOI: 10.1016/0192-0561(90)90110-9

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  5 in total

1.  Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner.

Authors:  Rajeev Mehla; Shalmali Bivalkar-Mehla; Ruonan Zhang; Indhira Handy; Helmut Albrecht; Shailendra Giri; Prakash Nagarkatti; Mitzi Nagarkatti; Ashok Chauhan
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

2.  A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study.

Authors:  R G Tozer; S Burdette-Radoux; K Berlanger; M L Davis; R C Lohmann; J R Rusthoven; N Wainman; B Zee; L Seymour
Journal:  Invest New Drugs       Date:  2002-11       Impact factor: 3.850

3.  A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.

Authors:  Amy C Peterson; Helena Harlin; Theodore Karrison; Nicholas J Vogelzang; James A Knost; John W Kugler; Eric Lester; Everett Vokes; Thomas F Gajewski; Walter M Stadler
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

4.  Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro.

Authors:  C Scheid; J Prendiville; G Jayson; D Crowther; B Fox; G R Pettit; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

5.  A phase II study of bryostatin 1 in metastatic malignant melanoma.

Authors:  D J Propper; V Macaulay; K J O'Byrne; J P Braybrooke; S M Wilner; T S Ganesan; D C Talbot; A L Harris
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.